Boston Family Office LLC Sells 1,558 Shares of Merck & Co., Inc. (NYSE:MRK)

Boston Family Office LLC lowered its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 2.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 51,565 shares of the company’s stock after selling 1,558 shares during the period. Boston Family Office LLC’s holdings in Merck & Co., Inc. were worth $5,622,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Bare Financial Services Inc bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $30,000. RIA Advisory Group LLC acquired a new stake in Merck & Co., Inc. during the 4th quarter worth about $30,000. Tidemark LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter worth about $31,000. Finally, AlphaMark Advisors LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $34,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.1 %

MRK traded down $0.11 during trading hours on Thursday, reaching $125.79. The company’s stock had a trading volume of 3,205,838 shares, compared to its average volume of 7,955,764. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10. The stock has a market cap of $318.60 billion, a PE ratio of 140.30, a P/E/G ratio of 1.61 and a beta of 0.39. The business’s 50-day moving average is $128.43 and its 200-day moving average is $120.19. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.21 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The firm’s revenue was up 8.9% compared to the same quarter last year. As a group, equities research analysts predict that Merck & Co., Inc. will post 8.69 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date of this dividend is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.22%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Merck & Co., Inc. in a report on Thursday, April 18th. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. UBS Group raised their price target on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. TheStreet lowered shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Finally, Berenberg Bank upped their price target on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Monday, April 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.33.

Get Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.